7024-58-0

Basic information

• Product Name: 2-Cyclopropylpyrimidine-4,6-diol
• Synonyms: 2-Cyclopropylpyrimidine-4,6-diol
• CAS NO: 7024-58-0
• Molecular Formula: C7H8N2O2
• Molecular Weight: 152.15062
• Mol File: 7024-58-0.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Cyclopropylpyrimidine-4,6-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Cyclopropylpyrimidine-4,6-diol(7024-58-0)
• EPA Substance Registry System: 2-Cyclopropylpyrimidine-4,6-diol(7024-58-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 7024-58-0(Hazardous Substances Data)

Upstream product

• 54070-74-5 cyclopropanecarboxamidine 
• 105-53-3 diethyl malonate 
• 108-13-4 malonodiamide 
• 4606-07-9 ethyl cyclopropylcarboxylate 
• 57297-29-7 cyclopropylcarboxamidine hydrochloride 
• 108-59-8 malonic acid dimethyl ester 

Downstream Products

• 75438-77-6 2-cyclopropyl-4,6-dihydroxy-5-nitro-pyrimidine 
• 7043-09-6 4,6-dichloro-2-cyclopropylpyrimidine 
• 75438-78-7 2-cyclopropyl-4,6-dichloro-5-nitro-pyrimidine 
• 811802-33-2 2-cyclopropyl-4,6-diisopropoxypyrimidine 
• 70058-41-2 2-Cyclopropyl-4-hydroxy-6-methoxypyrimidin 
• 1305117-30-9 N₄-{[(2S)-4-benzylmorpholin-2-yl]methyl}-6-chloro-2-cyclopropylpyrimidine-4,5-diamine 
• 1305117-31-0 3-{[(2R)-4-benzylmorpholin-2-yl]methyl}-7-chloro-5-cyclopropyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 1305115-67-6 3-{[(2R)-4-benzylmorpholin-2-yl]methyl}-5-cyclopropyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine 

Relevant articles and documents

PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Novel Compounds

The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

Discovery of a potent nicotinic acid receptor agonist for the treatment of dyslipidemia

Nicotinic acid has been used clinically for decades to control serum lipoproteins. Nicotinic acid lowers very low-density lipoprotein (VLDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, and lipoprotein-a (LPa), and it is also effective in raising high-density lipoprotein (HDL)-cholesterol. However, nicotinic acid has several side effects in clinical use. The most notable is intense cutaneous vasodilation "flushing"+ on the upper body and face. We discovered a pyranopyrimidinedione series to be nicotinic acid receptor agonists. A potent nicotinic acid receptor agonist from this series {5-(3-cyclopropylpropyl)-2-(difluoromethyl)-3H-pyrano[2,3-d] pyrimidine-4,7-dione}with reduced flushing side effect in dogs was identified.